Supernus Pharmaceuticals annual return on assets (roa)
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Supernus Pharmaceuticals Return on Assets (ROA) Growth & History (SUPN)
Supernus Pharmaceuticals's return on assets (roa) was −2.73% for fiscal 2025.
View full Supernus Pharmaceuticals company overviewSupernus Pharmaceuticals annual return on assets (roa) history
| Fiscal year | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −2.73% | −8.32 pp |
| 2024 | 2024-12-31 | 5.58% | +5.50 pp |
| 2023 | 2023-12-31 | 0.09% | −3.49 pp |
| 2022 | 2022-12-31 | 3.58% | +0.23 pp |
| 2021 | 2021-12-31 | 3.35% | −6.18 pp |
| 2020 | 2020-12-31 | 9.53% | −1.05 pp |
| 2019 | 2019-12-31 | 10.58% | −5.26 pp |
| 2018 | 2018-12-31 | 15.83% | +0.22 pp |
| 2017 | 2017-12-31 | 15.61% | −21.01 pp |
| 2016 | 2016-12-31 | 36.62% | +28.05 pp |
| 2015 | 2015-12-31 | 8.57% | +17.39 pp |
| 2014 | 2014-12-31 | −8.82% | +81.21 pp |
| 2013 | 2013-12-31 | −90.03% | −27.36 pp |
| 2012 | 2012-12-31 | −62.66% | — |
Supernus Pharmaceuticals quarterly return on assets (roa)
Q4.12
Q1.13
Q2.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −7.82% | −12.60 pp |
| Q1 2026 | 2026-03-31 | −2.04% | −6.71 pp |
| Q4 2025 | 2025-12-31 | −2.73% | −8.32 pp |
| Q3 2025 | 2025-09-30 | −1.38% | −5.93 pp |
| Q2 2025 | 2025-06-30 | 4.78% | +4.38 pp |
| Q1 2025 | 2025-03-31 | 4.67% | +5.67 pp |
| Q4 2024 | 2024-12-31 | 5.58% | +5.50 pp |
| Q3 2024 | 2024-09-30 | 4.54% | +2.82 pp |
| Q2 2024 | 2024-06-30 | 0.40% | −2.50 pp |
| Q1 2024 | 2024-03-31 | −1.00% | −4.04 pp |
| Q4 2023 | 2023-12-31 | 0.09% | −3.49 pp |
| Q3 2023 | 2023-09-30 | 1.72% | −0.60 pp |
| Q2 2023 | 2023-06-30 | 2.90% | −0.62 pp |
| Q1 2023 | 2023-03-31 | 3.03% | −1.63 pp |
| Q4 2022 | 2022-12-31 | 3.58% | +0.23 pp |
| Q3 2022 | 2022-09-30 | 2.32% | −3.01 pp |
| Q2 2022 | 2022-06-30 | 3.52% | −3.02 pp |
| Q1 2022 | 2022-03-31 | 4.66% | −3.58 pp |
| Q4 2021 | 2021-12-31 | 3.35% | −6.18 pp |
| Q3 2021 | 2021-09-30 | 5.33% | −4.55 pp |
| Q2 2021 | 2021-06-30 | 6.54% | −2.71 pp |
| Q1 2021 | 2021-03-31 | 8.24% | −2.25 pp |
| Q4 2020 | 2020-12-31 | 9.53% | −1.05 pp |
| Q3 2020 | 2020-09-30 | 9.88% | −0.55 pp |
| Q2 2020 | 2020-06-30 | 9.25% | −1.70 pp |
| Q1 2020 | 2020-03-31 | 10.49% | −0.64 pp |
| Q4 2019 | 2019-12-31 | 10.58% | −5.26 pp |
| Q3 2019 | 2019-09-30 | 10.43% | −4.67 pp |
| Q2 2019 | 2019-06-30 | 10.95% | −3.51 pp |
| Q1 2019 | 2019-03-31 | 11.13% | −1.65 pp |
| Q4 2018 | 2018-12-31 | 15.83% | +0.22 pp |
| Q3 2018 | 2018-09-30 | 15.10% | −2.18 pp |
| Q2 2018 | 2018-06-30 | 14.46% | −22.29 pp |
| Q1 2018 | 2018-03-31 | 12.78% | −24.64 pp |
| Q4 2017 | 2017-12-31 | 15.61% | −21.01 pp |
| Q3 2017 | 2017-09-30 | 17.28% | −19.80 pp |
| Q2 2017 | 2017-06-30 | 36.75% | +22.88 pp |
| Q1 2017 | 2017-03-31 | 37.43% | +26.63 pp |
| Q4 2016 | 2016-12-31 | 36.62% | +28.05 pp |
| Q3 2016 | 2016-09-30 | 37.08% | +29.65 pp |
| Q2 2016 | 2016-06-30 | 13.87% | +10.17 pp |
| Q1 2016 | 2016-03-31 | 10.79% | +6.28 pp |
| Q4 2015 | 2015-12-31 | 8.57% | +17.39 pp |
| Q3 2015 | 2015-09-30 | 7.43% | +36.17 pp |
| Q2 2015 | 2015-06-30 | 3.70% | +71.63 pp |
| Q1 2015 | 2015-03-31 | 4.52% | +97.88 pp |
| Q4 2014 | 2014-12-31 | −8.82% | +94.85 pp |
| Q3 2014 | 2014-09-30 | −28.74% | — |
| Q2 2014 | 2014-06-30 | −67.93% | +0.74 pp |
| Q1 2014 | 2014-03-31 | −93.37% | −2.71 pp |
| Q4 2013 | 2013-12-31 | −103.67% | −41.01 pp |
| Q2 2013 | 2013-06-30 | −68.67% | — |
| Q1 2013 | 2013-03-31 | −90.66% | — |
| Q4 2012 | 2012-12-31 | −62.66% | — |
Supernus Pharmaceuticals return on assets (roa) trends
Over the last five fiscal years, Supernus Pharmaceuticals's return on assets (roa) decreased from 9.53% to −2.73%, a change of −12.26 percentage points. The latest reported quarter, Q2 2026, shows −7.82%.
About the metric
What return on assets means
Return on assets measures profit relative to the assets used to generate it. It can help compare operating efficiency over time, although normal ROA differs substantially between asset-light and asset-intensive industries.
Calculation and source
How return on assets is calculated
TickerStat calculates annual ROA as reported net income divided by average total assets. Quarterly observations use trailing-12-month net income and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Supernus Pharmaceuticals source filings ↗Community posts
Supernus and Indivior report sales growth ahead of their expected merger closing
Supernus ($SUPN) reported third-quarter 2026 revenue of $226.8 million, up 18%, with Qelbree sales increasing 12% to $90.8 million and Onapgo contributing $17.1 million. Separately, merger partner Indivior ($INDV) posted revenue of $356 mil ...
Supernus confirms ONAPGO exclusivity and seeks a second supplier
Supernus ($SUPN) said the FDA has recognized orphan-drug exclusivity for ONAPGO, its apomorphine infusion treatment for motor fluctuations in adults with advanced Parkinson's disease. The seven-year protection period runs from the medicine' ...
